Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28286576 | 0.82 | NOTUM (0.56) | SIGMAR1NOTUMKEAP1NPC1RAB9A | |
| SCHEMBL30538064 | 0.79 | NOTUM (0.42) | NOTUMRAB9AALDH1A1 | |
| SCHEMBL30538087 | 0.72 | RXRA (0.40) | NOTUMKEAP1 | |
| SCHEMBL1131457 | 0.71 | NOTUM (0.44) | NOTUMALDH1A1 | |
| SCHEMBL16201982 | 0.70 | GAA (0.53) | NPC1RAB9AGLAALDH1A1L3MBTL1 | |
| SCHEMBL30038214 | 0.68 | KCNN4 (0.52) | NOTUMNPC1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL4302034 | 0.68 | KCNN4 (0.52) | NOTUMNPC1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL30538063 | 0.68 | NPC1 (0.48) | NPC1RAB9AGLAL3MBTL1OPRM1 | |
| SCHEMBL2357923 | 0.67 | ALDH1A1 (0.41) | SIGMAR1NPC1RAB9AGLAALDH1A1 | |
| SCHEMBL2749861 | 0.67 | GLA (0.35) | SIGMAR1NPC1RAB9AGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | SIGMAR1 2267/4885NOTUM 3642/4885KEAP1 3737/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | SIGMAR1 1219/4885NOTUM 3035/4885KEAP1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.